Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy - Scorecard - MDSpire
Advertisement
Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy
Clinical Scorecard: Impact of Direct-Acting Antiviral Therapy on Bone Microarchitecture and Inflammatory Cytokine Levels Following Resolution of Chronic Hepatitis C Infection
At a Glance
Category
Detail
Condition
Chronic Hepatitis C Virus (HCV) infection and its effects on bone health
Key Mechanisms
Chronic HCV infection induces inflammatory cytokines (TNF-α, IL-6, IL-18) that inhibit osteoblasts and stimulate osteoclasts, leading to bone deficits
Target Population
Adults with chronic HCV infection undergoing direct-acting antiviral (DAA) therapy and uninfected controls
Care Setting
Viral hepatitis and primary care clinics within a health system
Key Highlights
Chronic HCV infection is associated with lower bone mineral density and increased fracture risk, particularly at the hip.
DAA therapy achieves HCV cure in ≥94% of patients within 12 weeks.
Eighteen months after DAA initiation, cured patients showed decreases in inflammatory cytokines IL-18 and TNF-α but no significant changes in bone microarchitecture compared to controls.
Guideline-Based Recommendations
Diagnosis
Consider bone mineral density (BMD) screening by dual-energy X-ray absorptiometry (DXA) in people with chronic HCV, especially those with additional osteoporosis risk factors.
Management
Treat chronic HCV infection with direct-acting antivirals (DAAs) to achieve viral cure.
Monitor inflammatory cytokine levels as markers of systemic inflammation post-HCV cure.
Monitoring & Follow-up
Assess bone microarchitecture and volumetric BMD using high-resolution peripheral quantitative computed tomography (HR-pQCT) before and after DAA therapy.
Measure serum inflammatory cytokines (TNF-α, IL-6, IL-18) at baseline and follow-up to evaluate changes post-cure.
Risks
Persistent bone deficits may remain despite HCV cure; ongoing fracture risk assessment is warranted.
Inflammation-related bone loss mechanisms may not fully reverse within 18 months post-DAA therapy.
Patient & Prescribing Data
40 participants with chronic HCV initiating DAA therapy and achieving cure; 48 uninfected controls
DAA therapy effectively reduces inflammatory cytokines IL-18 and TNF-α but does not significantly improve bone microarchitecture within 18 months post-treatment.
Clinical Best Practices
Screen for osteoporosis in patients with chronic HCV infection, particularly those with additional risk factors.
Use HR-pQCT alongside DXA to evaluate detailed bone microarchitecture changes in research or specialized clinical settings.
Recognize that inflammation decreases after HCV cure but bone deficits may persist, necessitating continued bone health monitoring and management.
by Vincent Lo Re, Dean M Carbonari, Craig W Newcomb, Jessie Torgersen, Erica J Weinstein, Shanae M Smith, Katherine L Brecker, X Sherry Liu, Jay R Kostman, Stacey Trooskin, Rebecca A Hubbard, Joshua F Baker, Babette S Zemel, Mary B Leonard
